Den europeiske union - norsk - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Den europeiske union - norsk - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amyloidose, familiær - andre nervesystemet narkotika - onpattro er angitt for behandling av arvelig transthyretin-mediert amyloidose (hattr amyloidose) hos voksne pasienter med stadium 1 eller nivå 2 polynevropati.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillegg til andre legemidler til behandling av type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Den europeiske union - norsk - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiolmonohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. i tillegg til andre legemidler til behandling av type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Den europeiske union - norsk - EMA (European Medicines Agency)

astra zeneca ab - saxagliptin, dapagliflozin propanediol monohydrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - legemidler som brukes i diabetes - qtern, fast dose kombinasjon av saxagliptin og dapagliflozin, er indisert hos voksne i alderen 18 år og eldre med type 2 diabetes mellitus:for å bedre glykemisk kontroll når metformin og/eller sulphonylurea (su) og en av de monocomponents av qtern ikke gir tilstrekkelig glykemisk kontroll,når du allerede blir behandlet med gratis kombinasjon av dapagliflozin og saxagliptin. (se kapittel 4. 2, 4. 4, 4. 5 og 5. 1 for tilgjengelige data på kombinasjoner studert.

Den europeiske union - norsk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - olanzapin - schizophrenia; bipolar disorder - psykoleptiske - adultsolanzapine er angitt for behandling av schizofreni. olanzapine er effektivt i å opprettholde klinisk bedring i løpet videreføring terapi hos pasienter som har vist en innledende behandling svar. olanzapin er indisert for behandling av moderat til alvorlig manisk episode. hos pasienter med manisk episode har reagert på olanzapine behandling, olanzapin er indisert for forebygging av tilbakefall hos pasienter med bipolar lidelse.

Norge - norsk - Statens legemiddelverk

actavis group ptc ehf (1) - paroksetinhydroklorid - tablett, filmdrasjert - 20 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

gilead sciences ireland uc - remdesivir - covid-19 virus infection - veklury is indicated for the treatment of coronavirus disease 2019 (covid 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.

Den europeiske union - norsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - aripiprazol - schizofreni - psykoleptiske - vedlikehold behandling av schizofreni hos voksne pasienter stabilisert med muntlig aripiprazole.

Norge - norsk - Statens legemiddelverk

intervet international b.v. - fenbendazol - tablett - 500 mg